A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)

NCT00363636 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

340

Enrollment

INDUSTRY

Sponsor class

Stopped Enrollment challenges due to changes in standards of care resulted in premature termination. No safety or efficacy events factored into this action.

Conditions

Lymphoma, Non-Hodgkin's

Interventions

DRUG: Galiximab in combination with rituximab
DRUG: Rituximab in combination with placebo

Sponsor

Biogen